1 Erratum to: Clin Drug Investig (2013) 33:633–645 DOI 10.1007/s40261-013-0116-7
Page 644, Acknowledgments section which previously read
This study was sponsored by Pfizer SLU, Madrid, Spain. Statistical analysis was performed by the European Biometrics Institute and was funded by Pfizer SLU. Maria Pérez and Vanessa López Gómez were full-time employees of Pfizer SLU at the time of completion of the study and manuscript preparation. The others have no potential conflicts of interests that directly concern the content of this study.
Should read
This study was sponsored by Pfizer SLU, Madrid, Spain. The first draft of the manuscript was written by Almudena Pardo Mateos (Albiotech consultores, SL, Madrid, Spain) with funding provided by Pfizer SLU. Statistical analysis was performed by the European Biometrics Institute and was funded by Pfizer SLU. Maria Pérez and Vanessa López Gómez were full-time employees of Pfizer SLU at the time of completion of the study and manuscript preparation. The others have no potential conflicts of interests that directly concern the content of this study.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40261-013-0116-7.
Rights and permissions
About this article
Cite this article
Blanco Tarrio, E., Gálvez Mateos, R., Zamorano Bayarri, E. et al. Erratum to: Effectiveness of Pregabalin as Monotherapy or Combination Therapy for Neuropathic Pain in Patients Unresponsive to Previous Treatments in a Spanish Primary Care Setting. Clin Drug Investig 34, 371 (2014). https://doi.org/10.1007/s40261-014-0185-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-014-0185-2